Werewolf Therapeutics revenue was $1.89M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $0.0, down N/A from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, HOWL annual revenue was $1.9M, with -90.5% growth year-over-year.
HOWL past revenue growth
How has HOWL's revenue growth performed historically?
Werewolf Therapeutics (NASDAQ: HOWL) reported Q4 2024 revenue of $0.00 up 100% year over year. In the same quarter last year, Werewolf Therapeutics's revenue was $1.50 million.
What was Werewolf Therapeutics's revenue in 2024?
Werewolf Therapeutics's annual revenue for the twelve months ending Dec 31, 2024 was $1.89 million, a 90.55% decrease year over year.
How much does Werewolf Therapeutics make in a day?
Based on Werewolf Therapeutics annual revenue for the past five years, HOWL makes an average of $20,947.40 per day.
What was Werewolf Therapeutics's annual revenue growth in the past year?
As of Q2 2025, Werewolf Therapeutics's revenue has grown -90.55% year over year. This is 588.24 percentage points lower than the US Biotechnology industry revenue growth rate of 497.69%. Werewolf Therapeutics's revenue in the past year totaled $1.89 million.
How much does Werewolf Therapeutics make in a year?
Werewolf Therapeutics's revenue by year for the past five years is:
Werewolf Therapeutics's revenue for the twelve months ending Dec 31, 2024 was $1.89 million, a 90.55% decrease year over year.
Werewolf Therapeutics's annual revenue for Dec 31, 2023 was $19.94 million, a 21.6% increase from 2022.
Werewolf Therapeutics's annual revenue for 2022 was $16.40 million, a Infinity% increase from 2021.
Werewolf Therapeutics's annual revenue for 2021 was $0.00, a N/A decrease from 2020.
Werewolf Therapeutics's annual revenue for 2020 was $0.00, a N/A decrease from 2019.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.